Asfotase alfa

Drug Profile

Asfotase alfa

Alternative Names: ALXN1215; Asfotase alpha; ENB-0040; Strensiq

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Enobia Pharma
  • Developer Alexion Pharmaceuticals
  • Class Recombinant fusion proteins
  • Mechanism of Action Alkaline phosphatase stimulants; Esterase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypophosphatasia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypophosphatasia
  • Preclinical Neurofibromatoses

Most Recent Events

  • 14 Dec 2016 Launched for Hypophosphatasia in Germany (SC) before December 2016
  • 16 Sep 2016 Efficacy data from a phase II trial in Hypophosphatasia presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research-2016 (ASBMR-2016)
  • 12 Jul 2016 Preclinical trials in Neurofibromatosis in USA (unspecified route) before July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top